Other (Not applicable)

Other

US Experimental IV, Oral 5 Clinical Trials
Variable depending on specific agent

Description

"Other" represents a non-specific category encompassing various therapeutic agents used in colorectal cancer treatment that do not fit into standard drug classifications. Based on the clinical trial context, this likely includes dose-modified chemotherapy regimens, combination protocols, or supportive care interventions used in neoadjuvant therapy for locally advanced rectal cancer. These agents are typically employed as part of multimodal treatment approaches, particularly in elderly patients or those requiring organ preservation strategies.

Mechanism of Action

The mechanism of action varies depending on the specific agent or intervention classified under this category. Many involve DNA damage through alkylation or antimetabolite pathways when referring to modified chemotherapy protocols. The molecular targets and pathways differ based on the individual components of the treatment regimen.

Molecular Targets

Side Effects

Fatigue Nausea Diarrhea Neutropenia Peripheral neuropathy Mucositis Hand-foot syndrome Thrombocytopenia

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT07448077 Phase 2
Recruiting
Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC
China
NCT06758830 Phase 2
Recruiting
Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.
Lithuania
NCT06275958 Phase 3
Recruiting
DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer
Netherlands
NCT02031939 Phase 3
Unknown
Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
China
NCT02709811 Phase 1
Archived
Safety and Feasibility of Electrochemotherapy in Unresectable Colorectal Adenocarninoma Liver Metastases